AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26468228 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell immunity against stem-cell antigen SOX2
Number of subjects: 305
Study 26468228 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of PD-L1 on tumor and infiltrating T cells
Number of subjects: 305
Study 26468991 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable, long-duration, low-intensity ultrasonic device applied for 4 hours a day, at least 5 times per week over 6 weeks.
Number of subjects: 25
Study 26469381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 45
Study 26469381 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 45
Study 26471212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DM/Q) 20/10 mg twice daily
Number of subjects: 134
Study 26471772 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased femoral offset (FO) group (more than 5 mm reduction)
Number of subjects: 250
Study 26471772 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored femoral offset (FO) group (within 5 mm restoration)
Number of subjects: 250
Study 26471772 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased femoral offset (FO) group (more than 5 mm increment)
Number of subjects: 250
Study 26471772 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 250
Study 26471772 — intervention group
Group type: EXPERIMENTAL
Intervention: Global FO reduction
Number of subjects: 250
Study 26471772 — intervention group
Group type: COMPARATOR
Intervention: Incidence of residual hip pain and analgesics use
Number of subjects: 250
Study 26471854 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength and quadriceps activation failure (QAF)
Number of subjects: 52
Study 26471854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of strength by QAF
Number of subjects: 52
Study 26471917 — intervention group
Group type: EXPERIMENTAL
Intervention: Acessa Guidance System
Number of subjects: 5
Study 26472037 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic treatment for tracheobronchitis
Number of subjects: 2960
Study 26472037 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate antibiotic treatment for tracheobronchitis
Number of subjects: 2960
Study 26472037 — intervention group
Group type: COMPARATOR
Intervention: Ventilator-associated pneumonia
Number of subjects: 2960
Study 26472037 — intervention group
Group type: COMPARATOR
Intervention: Tracheobronchitis
Number of subjects: 2960
Study 26472037 — intervention group
Group type: COMPARATOR
Intervention: No ventilator-associated lower respiratory tract infections
Number of subjects: 2960
Study 26472037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheobronchitis and pneumonia
Number of subjects: 2960
Study 26472629 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with Huntington's disease mutation (1,007)
Number of subjects: 1305
Study 26472629 — intervention group
Group type: EXPERIMENTAL
Intervention: Companion ratings
Number of subjects: 1305
Study 26472629 — intervention group
Group type: COMPARATOR
Intervention: Controls (298)
Number of subjects: 1305
Study 26472751 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg twice daily continuously for 48 weeks plus rituximab 375 mg/m(2) weekly ×8
Number of subjects: 64
Study 26472751 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib plus rituximab
Number of subjects: 64
Study 26473643 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9291 at doses of 20 to 80 mg/day
Number of subjects: 4
Study 26473643 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9291
Number of subjects: 4
Study 26473774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully endoscopic transsphenoidal surgery (performed by a less experienced surgeon)
Number of subjects: 135
Study 26473774 — intervention group
Group type: COMPARATOR
Intervention: Microscopic transsphenoidal surgery (performed by a very experienced surgeon)
Number of subjects: 135
Study 26474010 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release quetiapine (quetiapine XR)
Number of subjects: 0
Study 26474010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26474292 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted endurance exercise (LC) with EAA supplementation (10 g EAA, 3.6 g leucine)
Number of subjects: 40
Study 26474292 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional endurance exercise (CE) with EAA supplementation (10 g EAA, 3.6 g leucine)
Number of subjects: 40
Study 26474292 — intervention group
Group type: COMPARATOR
Intervention: Weighted endurance exercise (LC) with control drink (non-nutritive)
Number of subjects: 40
Study 26474292 — intervention group
Group type: COMPARATOR
Intervention: Conventional endurance exercise (CE) with control drink (non-nutritive)
Number of subjects: 40
Study 26474455 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic score based on five SNPs (PSMB10, TNFRSF10D, PSMB2, PPARD, CYP26B1)
Number of subjects: 437
Study 26474455 — intervention group
Group type: EXPERIMENTAL
Intervention: CML-risk-allele score
Number of subjects: 437
Study 26474455 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk alleles from haplotype analysis
Number of subjects: 437
Study 26474455 — intervention group
Group type: COMPARATOR
Intervention: Single SNP association analysis
Number of subjects: 437
Study 26474521 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by local excision (capecitabine 725 mg/m² twice daily, oxaliplatin 50 mg/m², radiation 50.4 Gy total)
Number of subjects: 79
Study 26474521 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by local excision
Number of subjects: 79
Study 26474521 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after neoadjuvant chemoradiotherapy
Number of subjects: 79
Study 26474734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel occult microscopic endometriosis (BOME) present
Number of subjects: 103
Study 26474734 — intervention group
Group type: COMPARATOR
Intervention: Bowel occult microscopic endometriosis (BOME) absent
Number of subjects: 103
Study 26474738 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart Rate (RHR) groups
Number of subjects: 19200
Study 26474738 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 19200
Study 26474738 — intervention group
Group type: EXPERIMENTAL
Intervention: AAA incidence
Number of subjects: 19200
Study 26474775 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat; 22% from monounsaturated fatty acids)
Number of subjects: 642
Study 26474775 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<28% fat)
Number of subjects: 642
Study 26474775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 642
Study 26475140 — intervention group
Group type: EXPERIMENTAL
Intervention: AMT-PET scanning
Number of subjects: 21
Study 26475205 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT (Fractional Flow Reserve Computed Tomography)
Number of subjects: 584
Study 26475205 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 584
Study 26475205 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 584
Study 26475445 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (administered at 0, 6, and 12 months)
Number of subjects: 0
Study 26475445 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 0
Study 26475445 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term surveillance from phase 3 studies and phase 2b study
Number of subjects: 0
Study 26475577 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal behaviour prior to first presentation of psychosis and during a 3-year follow-up
Number of subjects: 397
Study 26475577 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depressive symptoms and cannabis use
Number of subjects: 397
Study 26475577 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Early' attempters characteristics
Number of subjects: 397
Study 26475577 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Late' attempters characteristics
Number of subjects: 397
Study 26475577 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programmes targeting phase-specific risk factors
Number of subjects: 397
Study 26475726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone, Azithromycin, and Montelukast (FAM)
Number of subjects: 36
Study 26476290 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir (25/150/100mg once daily) and dasabuvir (250mg twice daily) for 12 weeks
Number of subjects: 60
Study 26476290 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Number of subjects: 60
Study 26476398 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1 (MOLLI)
Number of subjects: 34
Study 26476398 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1 (ShMOLLI)
Number of subjects: 34
Study 26476398 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 relaxation times
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: T2-ratio
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: EGEr
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: LGE
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: LLC
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: ECV MOLLI
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: ECV ShMOLLI
Number of subjects: 34
Study 26476398 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal strain
Number of subjects: 34
Study 26476398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined native parameters (T1, T2, and longitudinal strain)
Number of subjects: 34
Study 26476503 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (echo)
Number of subjects: 201
Study 26476503 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed enhancement cardiac magnetic resonance (DE-CMR)
Number of subjects: 201
Study 26476503 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast echocardiography
Number of subjects: 201
Study 26476503 — intervention group
Group type: COMPARATOR
Intervention: Contrast echocardiography
Number of subjects: 201
Study 26476503 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-based apical wall motion score
Number of subjects: 201
Study 26477337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 41
Study 26477337 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 41
Study 26477497 — intervention group
Group type: EXPERIMENTAL
Intervention: New AMH immunoassay method (Ansh Labs)
Number of subjects: 45
Study 26477820 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minor allele rs1050851 in NFKBIA gene
Number of subjects: 401
Study 26477820 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minor allele rs2233417 in NFKBIA gene
Number of subjects: 401
Study 26477820 — intervention group
Group type: COMPARATOR
Intervention: Presence of minor alleles in NFKBIA SNPs
Number of subjects: 401
Study 26478682 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 52
Study 26479222 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic dosing regimen, specific details not available
Number of subjects: 0
Study 26479222 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study 26479487 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for treatment-resistant MDD and BPII depression
Number of subjects: 1098
Study 26479487 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for treatment-resistant MDD
Number of subjects: 1098
Study 26479487 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for treatment-resistant BPII depression
Number of subjects: 1098
Study 26481067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following total or sub-total gastrectomy
Number of subjects: 0
Study 26481067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following pancreatic resection
Number of subjects: 0
Study 26481067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following liver resection without hepatico-intestinal anastomosis
Number of subjects: 0
Study 26481067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following rectal resection
Number of subjects: 0
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit fibroatheromas (FAs) classified as proximal (<20 mm), mid (20 to 40 mm), and distal (>40 mm) based on distance from the ostium to the maximum necrotic core site.
Number of subjects: 697
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from the ostium to the maximum necrotic core site (per mm)
Number of subjects: 697
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque burden (per 10%)
Number of subjects: 697
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel area (per mm²)
Number of subjects: 697
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium presence
Number of subjects: 697
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Right coronary artery location
Number of subjects: 697
Study 26481843 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel area
Number of subjects: 697
Study 26481915 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-focused anxiety (HFA)
Number of subjects: 110
Study 26481915 — intervention group
Group type: EXPERIMENTAL
Intervention: General anxiety
Number of subjects: 110
Study 26481915 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 110
Study 26481915 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 110
Study 26481915 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-focused anxiety predictors
Number of subjects: 110
Study 26482301 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin treatment
Number of subjects: 35
Study 26482312 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (10 mg/kg/day for CLCR >50 ml/min; 7.5 mg/kg/day for CLCR 30-49 ml/min)
Number of subjects: 78
Study 26482312 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (historical control)
Number of subjects: 78
Study 26482312 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 78
Study 26482312 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 78
Study 26482357 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions at individual, relational, community, and institutional levels
Number of subjects: 0
Study 26482357 — intervention group
Group type: EXPERIMENTAL
Intervention: Research on personal, situational, and socio-cultural factors
Number of subjects: 0
Study 26482357 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health recognition of violence
Number of subjects: 0
Study 26482357 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions suggested in the review
Number of subjects: 0
Study 26482376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days) in addition to standard therapy
Number of subjects: 80
Study 26482376 — intervention group
Group type: COMPARATOR
Intervention: Hydration (same volume per day)
Number of subjects: 80
Study 26482769 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 0
Study 26482769 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 26482769 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 0
Study 26482895 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD) via endovascular radiofrequency ablation (RFA) of the renal arteries, with continued full-dose antihypertensive therapy (4.1 drugs) including diuretics.
Number of subjects: 60
Study 26482895 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 60
Study 26482997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellix EndoVascular Aneurysm Sealing system
Number of subjects: 150
Study 26483003 — intervention group
Group type: EXPERIMENTAL
Intervention: Misago stent
Number of subjects: 261
Study 26483003 — intervention group
Group type: EXPERIMENTAL
Intervention: Misago stent (U.S. patients)
Number of subjects: 261
Study 26483004 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Stent Graft System (main stent graft diameter 28 to 42 mm, branch stent graft diameter 10 to 14 mm)
Number of subjects: 9
Study 26483004 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Stent Graft System
Number of subjects: 9
Study 26483097 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII) LVAD support
Number of subjects: 200
Study 26483097 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management (OMM)
Number of subjects: 200
Study 26483098 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) placement
Number of subjects: 0
Study 26483108 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-based LDL-C lowering therapy
Number of subjects: 0
Study 26483108 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26483193 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic primary care (Sample A)
Number of subjects: 480
Study 26483193 — intervention group
Group type: COMPARATOR
Intervention: Gainfully employed population (Sample B)
Number of subjects: 480
Study 26483193 — intervention group
Group type: COMPARATOR
Intervention: Secondary care rehabilitation clinic (Sample C)
Number of subjects: 480
Study 26483193 — intervention group
Group type: COMPARATOR
Intervention: Secondary care clinics (Sample D)
Number of subjects: 480
Study 26483516 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-based therapy (750 mg every 8 hours, 1125 mg if on efavirenz) plus Peg-IFNα2a (180 μg/week) and ribavirin (800 mg/day) for 12 weeks, followed by Peg-IFNα2a and ribavirin alone for 12 or 36 weeks depending on patient type.
Number of subjects: 162
Study 26483516 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir-based therapy
Number of subjects: 162
Study 26485680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 29
Study 26486356 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 4 months
Number of subjects: 46
Study 26486356 — intervention group
Group type: COMPARATOR
Intervention: Control group (OLM)
Number of subjects: 46
Study 26486356 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 4 months in OOM group
Number of subjects: 46
Study 26486517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar (2 mg/kg)
Number of subjects: 29
Study 26486517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar in combination with docetaxel
Number of subjects: 29
Study 26486517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar in combination with vinorelbine
Number of subjects: 29
Study 26486517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar
Number of subjects: 29
Study 26486974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/day) for 180 days
Number of subjects: 12
Study 26486974 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy normolipidemic age-matched nonobese males), n = 12
Number of subjects: 12
Study 26487230 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography (EUS)
Number of subjects: 24
Study 26487230 — intervention group
Group type: EXPERIMENTAL
Intervention: White Light Endoscopy (WLE)
Number of subjects: 24
Study 26487230 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE)
Number of subjects: 24
Study 26487230 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert evaluation of CLE
Number of subjects: 24
Study 26487580 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic phenotyping of plasma
Number of subjects: 134
Study 26487580 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent validation cohort
Number of subjects: 134
Study 26487748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limit of normal criterion
Number of subjects: 164
Study 26487748 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutoff values (80% predicted value and FEV1/FVC <0.7)
Number of subjects: 164
Study 26488168 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health promotion program
Number of subjects: 30
Study 26488192 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 1425
Study 26488192 — intervention group
Group type: COMPARATOR
Intervention: Axillary radiotherapy (ART)
Number of subjects: 1425
Study 26488691 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement followed by 12 weeks of nonsurgical treatment
Number of subjects: 100
Study 26488691 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment alone
Number of subjects: 100
Study 26488691 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Number of subjects: 100
Study 26488691 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 100
Study 26488758 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (specific dosage not mentioned)
Number of subjects: 32
Study 26488758 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gy irradiation
Number of subjects: 32
Study 26488758 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene modulation (FAS modulation)
Number of subjects: 32
Study 26489933 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with delay in TF recovery
Number of subjects: 24
Study 26489933 — intervention group
Group type: COMPARATOR
Intervention: Model without delay in TF recovery
Number of subjects: 24
Study 26489933 — intervention group
Group type: COMPARATOR
Intervention: Model using TF with additional TI and PCR data
Number of subjects: 24